Lundbeck Q3 2019 Financial Results

Third study in brexpiprazole pivotal programme in agitation Alzheimer's progresses as planned Agitation in Alzheimer's (AAD) >20% of individuals in a community setting and >50% of nursing home residents with dementia have agitation * * 1.5-2m dementia patients in the U.S. with agitation / aggression x No FDA approved medication * Associated with increased caregiver burden, decreased functioning, earlier nursing home placement Study objective¹) To compare the efficacy of 2 doses of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type (n = ~225) Third study out of three in the pivotal programme (phase III): * Brexpiprazole (fixed dose 2mg and 3mg) and placebo ★ Primary endpoint: Cohen-Mansfield Agitation Inventory (CMAI) total score (Week 12) * Secondary endpoint: Clinical Global Impression Severity of Illness (CGI-S) score * Headline results due early 2021 - Fast Track designation granted February 2016 1) Clinicaltrials.gov ID: NCT03548584 27 Lundbeck

View entire presentation